Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
John Buse, MD, PhD
Advertisement
Articles by John Buse, MD, PhD
Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease.
Advertisement
Latest Updated Articles
SOUL Findings Highlight Cardiovascular Benefits Beyond Glycemic Control With Oral GLP-1Published: March 30th 2025 | Updated:
- Thiazolidiones in the Treatment of Type 2 Diabetes: A Clinician's Perspective
Published: August 1st 2000 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Evinacumab-dgnb Approval for Children as Young as 1 Year With HoFH
2
In Primary Care–Oncology Collaboration, the Baton Goes Both Ways
3
Trust and Transparency Key for Leveraging AI to Expand Access to Precision Oncology
4
FDA Approves Imlunestrant for ER+ and HER2-Negative Breast Cancer
5
